Western blotting results further showed markedly elevated CD45 and CD11b expression in the SCI group compared with that in the sham group (CD45, 5.58-fold; CD11b, 2.69-fold; P<0.01), which significantly decreased after CLL administration in the SCI+CLL group (CD45, 0.59-fold, P<0.05; CD11b, 0.50-fold, P<0.05) (Fig. 5F-H). This evidence concerns the gene ITGAM and B-cell chronic lymphocytic leukemia.